The present invention relates to modified mitochondria comprising an antibody binding to a cancer cell-specific protein and cytosine deaminase, in the mitochondrial outer membrane It was confirmed that, when a pancreatic cancer cell line was co-treated with the mitochondria according to the present invention and 5-FC, cytotoxicity induced by 5-FC treatment was significantly increased. The effect was confirmed to result from the conversion of 5-FC to 5-FU by cytosine deaminase expressed on the mitochondrial outer membrane, inducing apoptosis of pancreatic cancer cells. Therefore, it is considered that the modified mitochondria of the present invention can be effectively used in anticancer treatment using 5-FC as an anticancer agent.
C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to a method for freezing and/or freeze-drying mitochondria isolated from cells, and a use of frozen and/or freeze-dried mitochondria. The frozen mitochondria according to the present invention showed similarity to non-frozen mitochondria in terms of anti-inflammatory activity and activity of energy metabolism-related enzymes. Also, the freeze-dried mitochondria showed similar levels of anti-inflammatory activity, activity of energy metabolism-related enzymes, and long-term preservation efficacy after recovery to those in the mitochondria before freeze-drying. Therefore, allowing isolated mitochondria to find a wide spectrum of applications in the treatment of various diseases caused by mitochondrial dysfunction or impairment, the frozen and/or freeze-dried mitochondria according to the present invention is expected to greatly enhance the commercial availability of therapeutics containing mitochondria.
The present invention relates to a preservation solution composition for the preservation of an isolated cell, tissue, or organ, comprising isolated mitochondria; and a method for preserving an isolated cell, tissue, or organ by using the same. The preservation solution composition according to the present invention has excellent long-term preservability while maintaining the activity of isolated cell, tissue, or organ. Therefore, the present invention may be effectively used in the transplantation medicine field for ultimately improving transplant success rates and in the regenerative medicine field and the like.
The present invention relates to a pharmaceutical composition for preventing or treating fibrosis and, more specifically, to a pharmaceutical composition for preventing or treating fibrosis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from fibrosis such as pulmonary fibrosis, hepatic fibrosis and renal fibrosis, the fibrosis of tissues may be inhibited. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of fibronectin, CTGF2, α-SMA, collagen 1A and the like during treatment of TGF-β. Therefore, the pharmaceutical composition according to the present invention may be effectively used in the prevention or treatment of fibrosis.
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (Republic of Korea)
Inventor
Kang, Young Cheol
Han, Kyuboem
Kim, Chun-Hyung
Kim, Soomin
Zhang, Yin Hua
Cui, Hui Xing
Abstract
The present invention relates to a pharmaceutical composition for preventing or treating a hypertensive disease, comprising isolated mitochondria as an active ingredient. When the pharmaceutical composition comprising isolated mitochondria as an active ingredient, according to the present invention, is administered to an individual suffering from a hypertensive disease, the blood pressure of the individual can be lowered. In addition, the pharmaceutical composition can restore damaged blood vessels in the placenta of individuals suffering from hypertension in pregnancy among hypertensive diseases. Moreover, the pharmaceutical composition can normalize side effects, such as low fetal weight and fetal growth restriction, due to a hypertensive disease in pregnancy. Therefore, the pharmaceutical composition according to the present invention can be effectively used in the prevention or treatment of hypertensive diseases, particularly hypertension in pregnancy and resistant hypertension.
The present invention relates to a mitochondrion containing a compound having the anticancer efficacy and uses thereof. It was confirmed that the mitochondrion efficiently deliver the compound to the tumor, and the anticancer effect of the mitochondrion containing the compound was confirmed. In particular, when an antibody or a fragment thereof that specifically binds to a tumor is bound to the surface of mitochondrion, the compound may be delivered specifically to the tumor. Therefore, the mitochondrion containing the compound according to the present invention may be effectively used for the treatment of cancer because the side effects of the compound are few.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
7.
PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING HEARING LOSS OR TINNITUS, COMPRISING MITOCHONDRIA AS ACTIVE INGREDIENT
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (Republic of Korea)
Inventor
Kang, Young Cheol
Han, Kyuboem
Kim, Chun-Hyung
Kim, Soomin
Park, Min-Hyun
Lee, Ho Sun
Abstract
Provided is a pharmaceutical composition for preventing or treating hearing loss or tinnitus, the composition comprising mitochondria as an active ingredient. The pharmaceutical composition has the effects of preventing the apoptosis of inner ear cells due to damage and inhibiting hearing loss, and thus can effectively relieve or treat hearing loss or tinnitus.
Provided are a method for obtaining active mitochondria by freezing platelets and a use of isolated mitochondria, and more specifically, to a method for obtaining mitochondria by thawing platelets after freezing the same and a pharmaceutical composition containing the mitochondria obtained by the method as an active ingredient. The present disclosure, by providing a method for obtaining mitochondria by thawing platelets in a frozen state in a preservation solution, not only enables to obtain mitochondria in which the activity is stably maintained, but also enables to provide a commercial value for donor platelets that are discarded after refrigeration for a short period of time. Additionally, the pharmaceutical composition containing platelet-derived mitochondria obtained by the above method may be effectively used to treat various diseases caused by mitochondrial dysfunction.
The present invention relates to a method of freezing and/or freeze-drying mitochondria isolated from cells, and a use of frozen and/or freeze-dried mitochondria. The frozen mitochondria according to the present invention showed similarity to non-frozen mitochondria in terms of anti-inflammatory activity and activity of energy metabolism-related enzymes. Also, freeze-dried mitochondria showed similar levels of anti-inflammatory activity, activity of energy metabolism-related enzymes, and long-term preservation efficacy after recovery to those in the mitochondria before freeze-drying. Therefore, allowing isolated mitochondria to find a wide spectrum of applications in the therapy of various disorders caused by mitochondrial dysfunction or impairment, the frozen and/or freeze-dried mitochondria according to the present invention is expected to greatly enhance the commercial availability of therapeutics containing mitochondria.
Provided is a composition for injection containing isolated mitochondria. More specifically, provided is a liquid composition for injection containing glycine, saccharide, buffer, and mitochondria, and a pharmaceutical composition comprising the liquid composition for injection as an active ingredient. The liquid composition for injection according to the present disclosure is capable of securing the safety of a mitochondrial therapeutic and maintaining the activity of mitochondria, by enhancing the stability of mitochondria for prevention or treatment of mitochondria-related diseases and preventing and inhibiting formation of blood clots in the blood of a subject who is administered with the same. Accordingly, the pharmaceutical composition according to the present disclosure may solve the aggregation that may occur when mitochondria are administered in the body and thus enables to safely and effectively inject mitochondria into the body to be used for the purpose of preventing and treating various diseases caused by mitochondrial dysfunction.
The present invention relates to: a preservation solution composition for the preservation of isolated cells, tissues or organs, comprising isolated mitochondria; and a method for preserving isolated cells, tissues or organs by using same. A preservation solution composition according to the present invention has excellent long-term preservability while maintaining the activity of isolated cells, tissues or organs. Therefore, the present invention can be effectively used in the transplantation medicine field for ultimately improving transplant success rates and in the regenerative medicine field and the like.
The present invention relates to a pharmaceutical composition for preventing or treating fibrosis, containing a pheophorbide compound as an active ingredient. The pharmaceutical composition can effectively inhibit fibrosis of tissues by inhibiting signaling of TGF-β which causes fibrosis and inhibiting activation and expression of collagen and fibronectin, and is significantly superior in the anti-fibrotic activity compared to nintedanib or pirfenidone, which are commercially available therapeutic agents for pulmonary fibrosis, and therefore may be widely used in the prevention or treatment of fibrosis.
A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
A61P 11/00 - Drugs for disorders of the respiratory system
13.
PHARMACEUTICAL COMPOSITION FOR TREATING SEPSIS OR SYSTEMIC INFLAMMATORY RESPONSE SYNDROME, COMPRISING ISOLATED MITOCHONDRIA AS ACTIVE INGREDIENT
The present invention relates to a pharmaceutical composition for the treatment of sepsis or systemic inflammatory response syndrome (SIRS) comprising mitochondria as effective ingredient. When activated macrophages and monocytes are treated with mitochondria which are effective ingredient of the pharmaceutical composition of the present invention, expression of IL-1β, TNF-α and IL-6 which are pro-inflammatory cytokines can be restored to normal levels. Furthermore, when the pharmaceutical composition of the present invention is administered to a subject suffering from sepsis, the survival rate of the subject can be remarkably increased. Therefore, the pharmaceutical composition according to the present invention can be useful for the treatment of sepsis.
The present invention relates to a pharmaceutical composition for preventing or treating myositis. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating myositis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from myositis, inflammatory cells infiltrated into the muscle cells of the subject can be reduced. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of IL-1β, TNF-α, and IL-6, inflammatory cytokines. Therefore, the pharmaceutical composition according to the present invention can be usefully used for preventing or treating myositis.
The present invention relates to a pharmaceutical composition for preventing or treating fibrosis and, more specifically, to a pharmaceutical composition for preventing or treating fibrosis, comprising mitochondria as an active ingredient. When a pharmaceutical composition comprising exogenous mitochondria as an active ingredient, of the present invention, is administered to an individual afflicted with fibrosis such as pulmonary fibrosis, hepatic fibrosis and renal fibrosis, the fibrosis of tissues can be inhibited. In addition, the pharmaceutical composition of the present invention can effectively inhibit the expression of fibronetin, CTGF2, α-SMA, collagen 1A and the like during treatment of TGF-β. Therefore, a pharmaceutical composition according to the present invention can be effectively used in the prevention or treatment of fibrosis.
The present invention relates to mitochondria comprising a compound having anticancer efficacy and use thereof. It was confirmed that the mitochondria efficiently delivered the compound to tumors, and the anticancer effect of the mitochondria comprising a compound was confirmed. In particular, when binding an antibody that specifically binds to tumors or a fragment thereof to the surface of the mitochondria, tumor-specific delivery of the compound is possible. Thus, the mitochondria comprising a compound, according to the present invention, can be effectively used in cancer treatment due to fewer side effects of the compound.
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
The present invention relates to a method for obtaining active mitochondria by freeze storing platelets, and a use of the separated mitochondria and, more specifically, to a method for obtaining mitochondria by freezing and then thawing platelets and a pharmaceutical composition comprising as an active ingredient the mitochondria obtained by the method. The present invention provides a method for obtaining mitochondria by thawing platelets in a frozen state in a preservation solution, whereby mitochondria with activity stably maintained therein can be easily obtained and donated platelets which are discarded after cold storage within a short time can be provided with a commercial value. In addition, a pharmaceutical composition comprising platelet-derived mitochondria obtained by the method can be advantageously used for treating various diseases caused by mitochondrial dysfunction.
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
18.
INJECTION COMPOSITION CONTAINING ISOLATED MITOCHONDRIA, AND USE THEREOF
The present invention relates to an injection composition containing isolated mitochondria. More specifically, the present invention relates to a liquid injection composition containing glycine, sugars, a buffer and mitochondria, and a pharmaceutical composition containing the liquid injection composition as an active ingredient. The liquid injection composition according to the present invention strengthens the stability of mitochondria for prevention or treatment of mitochondria-related diseases and prevents and inhibits thrombogenesis in the blood of a subject to whom the composition is administered, and thus can ensure the safety of a mitochondrial therapeutic agent and maintain the activity of mitochondria. Therefore, a composition according to the present invention resolves aggregation, which can occur during the administration of mitochondria into the body, and thus, in order to prevent and treat various diseases caused by mitochondria dysfunction, mitochondria can be safely and effectively injected into the body.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/00 - Drugs for disorders of the nervous system
19.
Natural killer cell containing exogenous mitochondrium and pharmaceutical composition comprising same
An NK cells and PBMC, both having increased cytotoxicity are provided. Particularly, NK cells and PBMC which have exogenous mitochondria introduced thereinto potentiate the immune system of the human body to enhance a therapeutic effect on infectious diseases or cancer. Therefore, the NK cells and PBMC can be used in a composition for prevention or treatment of infectious diseases and cancer. Specially, autogenous NK cells and PBMC guarantee stability without the incurrence of an immune reaction, and thus would be expected to have high commercial activity.
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
Mitochondria modified by a targeting protein, according to one embodiment of the present invention, can be effectively delivered to a target. In addition, when a protein of interest bound to the modified mitochondria is delivered into a cell, various activities can be exhibited. The modified mitochondria can effectively cause cancer tissue death, and thus can also be used as an anticancer agent. Furthermore, various activities are exhibited according to a protein of interest loaded on modified mitochondria, and thus the modified mitochondria can be applied in the treatment of various diseases. Additionally, a fusion protein comprising a protein of interest and a fusion protein comprising a targeting protein, according to one embodiment of the present invention, can be used in order to modify mitochondria. Moreover, mitochondria modified with the fusion proteins exhibits various effects in a target cell.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 35/04 - Antineoplastic agents specific for metastasis
21.
PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING FIBROSIS, COMPRISING PHEOPHORBIDE COMPOUND AS ACTIVE INGREDIENT
The present invention relates to a pharmaceutical composition, for preventing or treating fibrosis, comprising a pheophorbide compound as an active ingredient. The present invention inhibits the activation and expression of collagen and fibronectin by inhibiting the signal transmission of TGF-β which is the cause of fibrosis, and thus can efficiently inhibit fiberization of tissues. The present invention also has notably superior anti-fibrotic activities over nintedanib or pirfenidone which are therapeutic agents for pulmonary fibrosis currently on the market, and thus will be widely used for preventing or treating fibrosis.
A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
A61P 43/00 - Drugs for specific purposes, not provided for in groups
22.
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MYOSITIS, COMPRISING ISOLATED MITOCHONDRIA AS ACTIVE INGREDIENT
The present invention relates to a pharmaceutical composition for preventing or treating myositis and, more specifically, to a pharmaceutical composition for preventing or treating myositis, comprising mitochondria as an active ingredient. When administered to an entity suffering from myositis, the pharmaceutical composition comprising foreign mitochondria as an active ingredient, according to the present invention, can reduce infiltrative inflammatory cells among myocytes of the entity. Also, the pharmaceutical composition according to the present invention effectively suppresses the expression of IL-1ß, TNF-a, and IL-6, which are inflammatory cytokines. Accordingly, the pharmaceutical composition according to the present invention can be beneficially used in the prevention or treatment of myositis.
The present invention relates to a pharmaceutical composition which is for treating sepsis or systemic inflammatory response syndrome, and contains mitochondria as an active ingredient. Treating activated macrophages and monocytes with mitochondria, which is the active ingredient of a pharmaceutical composition according to the present invention, can restore the expression of IL-1β, TNF-α, and IL-6, which are pro-inflammatory cytokines. In addition, administering the pharmaceutical composition according to the present invention to an individual with sepsis can significantly increase the survival rate of the individual. Thus, the pharmaceutical composition according to the present invention can be effectively used for treating sepsis.
The present invention relates to a pharmaceutical composition for preventing or treating myositis and, more specifically, to a pharmaceutical composition for preventing or treating myositis, comprising mitochondria as an active ingredient. When administered to an entity suffering from myositis, the pharmaceutical composition comprising foreign mitochondria as an active ingredient, according to the present invention, can reduce infiltrative inflammatory cells among myocytes of the entity. Also, the pharmaceutical composition according to the present invention effectively suppresses the expression of IL-1β, TNF-α, and IL-6, which are inflammatory cytokines. Accordingly, the pharmaceutical composition according to the present invention can be beneficially used in the prevention or treatment of myositis.
Mitochondria modified by a targeting protein, according to one embodiment of the present invention, can be effectively delivered to a target. In addition, when a protein of interest bound to the modified mitochondria is delivered into a cell, various activities can be exhibited. The modified mitochondria can effectively cause cancer tissue death, and thus can also be used as an anticancer agent. Furthermore, various activities are exhibited according to a protein of interest loaded on a modified mitochondria, and thus the modified mitochondria can be applied in the treatment of various diseases. Additionally, a fusion protein comprising a protein of interest and a fusion protein comprising a targeting protein, according to one embodiment of the present invention, can be used in order to modify mitochondria. Moreover, mitochondria modified with the fusion proteins exhibits various effects in a target cell.
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
C07K 14/395 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from fungi from yeasts from Saccharomyces
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
Mitochondria modified by a targeting protein, according to one embodiment of the present invention, can be effectively delivered to a target. In addition, when a protein of interest bound to the modified mitochondria is delivered into a cell, various activities can be exhibited. The modified mitochondria can effectively cause cancer tissue death, and thus can also be used as an anticancer agent. Furthermore, various activities are exhibited according to a protein of interest loaded on a modified mitochondria, and thus the modified mitochondria can be applied in the treatment of various diseases. Additionally, a fusion protein comprising a protein of interest and a fusion protein comprising a targeting protein, according to one embodiment of the present invention, can be used in order to modify mitochondria. Moreover, mitochondria modified with the fusion proteins exhibits various effects in a target cell.
C07K 14/395 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from fungi from yeasts from Saccharomyces
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
27.
Natural killer cell containing exogenous mitochondrium and pharmaceutical composition comprising same
An NK cells and PBMC, both having increased cytotoxicity are provided. Particularly, NK cells and PBMC which have exogenous mitochondria introduced thereinto potentiate the immune system of the human body to enhance a therapeutic effect on infectious diseases or cancer. Therefore, the NK cells and PBMC can be used in a composition for prevention or treatment of infectious diseases and cancer. Specially, autogenous NK cells and PBMC guarantee stability without the incurrence of an immune reaction, and thus would be expected to have high commercial activity.
C12N 5/078 - Cells from blood or from the immune system
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A61K 9/19 - Particulate form, e.g. powders lyophilised
The present invention relates to a pharmaceutical composition for prevention or treatment of rheumatoid arthritis and, more particularly, to a pharmaceutical composition comprising mitochondria as an effective ingredient for prevention or treatment of rheumatoid arthritis. When a foreign mitochondria pharmaceutical composition of the present invention is administered to a subject suffering from rheumatoid arthritis, the subject may have alleviated edema and rubefaction symptoms. In addition, the pharmaceutical composition of the present invention reduces an expression level of the inflammatory cytokine IL-6, but increases an expression level of the anti-inflammatory cytokine IL-10 in the subject. Therefore, the pharmaceutical composition according to the present invention can be effectively used for preventing or treating rheumatoid arthritis.
The present invention relates to a pharmaceutical composition containing mitochondria and, more specifically, to a pharmaceutical composition for preventing or treating muscle diseases or ischemic diseases, containing mitochondria as active ingredients. The pharmaceutical composition of the present invention contains heterologous mitochondria or cells comprising heterologous mitochondria, thereby enabling the mitochondrial activity of cells to which the same is administered to improve. Therefore, the pharmaceutical composition according to the present invention can be useful in the fundamental prevention or treatment of muscle diseases or ischemic diseases, which occur in relationship with the deterioration of mitochondrial function.
The present invention relates to a method for delivering exogenous mitochondria into cells and, more specifically, to a method for efficiently delivering, into the cytoplasm of target cells to be injected, mitochondria isolated from donor cells.
The present invention relates to a microneedle, to a mould for producing same, and to a production method for same. More specifically, the present invention concerns a microneedle for causing a skin-beautifying substance or drug to be absorbed via the skin, to a plastic mould for producing same, and to a production method for same.
patents
